Psoriasis patients switch biologics in new observational study
NCT ID NCT07449234
First seen Mar 09, 2026 · Last updated Apr 25, 2026 · Updated 5 times
Summary
This study follows 200 adults with moderate to severe psoriasis who switch from ustekinumab to guselkumab in routine care. Researchers will track how well the new drug controls skin symptoms and monitor for side effects over 52 weeks. The goal is to see if guselkumab is a safe and effective option after ustekinumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
LKH-Univ. Klinikum Graz
RECRUITINGGraz, 8036, Austria
Conditions
Explore the condition pages connected to this study.